Skip to navigation Skip to content

Clinical Trial: Nabiximols Oromucosal Spray as Add-on Therapy in People With Spasticity Due to MS


Treatment mode of action: To reduce spasticity
Number of Subjects: 446
Medication: Nabiximols Oromucosal Spray
Location: North Carolina
Institutions: Accellacare
1901 S. Hawthorne Road Suite 306 
Winston-Salem, North Carolina 27103 Contact Information
Tessa Santarpia


Jazz Pharmaceuticals


Accellacare is now enrolling men or women, age 18+, to participate in a research study in Winston-Salem, North Carolina. Participants must have been diagnosed with multiple sclerosis for at least 12 months. Participants also should be currently receiving optimized treatment with at least 1 oral anti-spasticity medication, and display spasticity symptoms, including muscle spasms.

This study includes a 28-day baseline period, a 12-week treatment period and a 2-week follow up period, throughout which participants will be closely monitored by healthcare providers. The treatment period involves 1 spray/day of the investigational product. Health insurance is not required, as participants receive all study medication and care at no cost, as well as financial reimbursement for time and travel.


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.